2003年加拿大呼吸道合胞病毒的预防
Prophylaxis of respiratory syncytial virus in Canada in 2003.
作者信息
Robinson Joan L, Lee Bonita E
机构信息
Department of Pediatrics, University of Alberta, Edmonton, Alberta.
出版信息
Paediatr Child Health. 2003 Dec;8(10):609-12. doi: 10.1093/pch/8.10.609.
Passive immunization of high-risk children with the humanized monoclonal antibody palivizumab is the mainstay of respiratory syncytial virus (RSV) prophylaxis in Canada in 2003. This product appears to be safe, and it prevents the majority of RSV hospitalizations in infants born before 36 weeks gestational age, and about half in children under 24 months of age with hemodynamically significant congenital heart disease. However, the high cost of palivizumab and the fact that at least 12 infants need to be treated throughout RSV season to prevent one hospitalization make it difficult to determine the ideal indications for the product. Because these high-risk infants account for a minority of RSV hospitalizations, it is desirable to search for a prophylactic strategy that is practical to apply in all infants.
2003年在加拿大，使用人源化单克隆抗体帕利珠单抗对高危儿童进行被动免疫是预防呼吸道合胞病毒（RSV）的主要方法。该产品似乎是安全的，它能预防大多数孕周小于36周的婴儿发生RSV住院，对于患有血流动力学显著先天性心脏病的24个月以下儿童，预防住院的比例约为一半。然而，帕利珠单抗成本高昂，而且在整个RSV流行季节至少需要治疗12名婴儿才能预防1例住院，这使得难以确定该产品的理想适用指征。由于这些高危婴儿占RSV住院病例的少数，因此需要寻找一种适用于所有婴儿的实用预防策略。
Zotero 插件